Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.

Belli V, Matrone N, Napolitano S, Migliardi G, Cottino F, Bertotti A, Trusolino L, Martinelli E, Morgillo F, Ciardiello D, De Falco V, Giunta EF, Bracale U, Ciardiello F, Troiani T.

J Exp Clin Cancer Res. 2019 Jun 4;38(1):236. doi: 10.1186/s13046-019-1230-z.

2.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.

Nature. 2019 Apr;568(7753):511-516. doi: 10.1038/s41586-019-1103-9. Epub 2019 Apr 10.

PMID:
30971826
3.

Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin.

Mannucci C, Dante G, Miroddi M, Facchinetti F, D'Anna R, Santamaria A, Lenti MC, Vannacci A, Calapai F, Perone M, Migliardi G, Alibrandi A, Navarra M, Calapai G.

J Matern Fetal Neonatal Med. 2019 Jan;32(1):125-128. doi: 10.1080/14767058.2017.1373761. Epub 2017 Sep 17.

PMID:
28868940
4.

Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.

Picco G, Petti C, Sassi F, Grillone K, Migliardi G, Rossi T, Isella C, Di Nicolantonio F, Sarotto I, Sapino A, Bardelli A, Trusolino L, Bertotti A, Medico E.

J Natl Cancer Inst. 2016 Oct 22;109(2). pii: djw209. Print 2017 Feb.

5.

C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.

D'Amico L, Belisario D, Migliardi G, Grange C, Bussolati B, D'Amelio P, Perera T, Dalmasso E, Dalle Carbonare L, Godio L, Comoglio P, Trusolino L, Ferracini R, Roato I.

Oncotarget. 2016 Jul 19;7(29):45525-45537. doi: 10.18632/oncotarget.9997.

6.

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.

Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D.

J Transl Med. 2016 May 5;14(1):119. doi: 10.1186/s12967-016-0872-2.

7.

The genomic landscape of response to EGFR blockade in colorectal cancer.

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE.

Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.

8.

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, Throsby M, Bertotti A, Trusolino L.

Clin Cancer Res. 2015 Dec 15;21(24):5519-31. doi: 10.1158/1078-0432.CCR-14-3066. Epub 2015 Aug 21.

9.

HER2 activating mutations are targets for colorectal cancer treatment.

Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R.

Cancer Discov. 2015 Aug;5(8):832-41. doi: 10.1158/2159-8290.CD-14-1211.

10.

The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling.

Rossi L, Forte D, Migliardi G, Salvestrini V, Buzzi M, Ricciardi MR, Licchetta R, Tafuri A, Bicciato S, Cavo M, Catani L, Lemoli RM, Curti A.

Exp Hematol. 2015 Nov;43(11):974-985.e1. doi: 10.1016/j.exphem.2015.07.003. Epub 2015 Jul 23.

PMID:
26213230
11.

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, Lupo B, Erriquez J, Isella C, Comoglio PM, Medico E, Tejpar S, Budinská E, Trusolino L, Bertotti A.

Sci Transl Med. 2015 Jan 28;7(272):272ra12. doi: 10.1126/scitranslmed.3010445.

12.

HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.

Pavan S, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M, Di Renzo MF.

Int J Cancer. 2014 Mar 15;134(6):1289-99. doi: 10.1002/ijc.28464. Epub 2013 Sep 18.

13.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.

Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2.

14.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L.

Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2.

15.

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.

Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A, Trusolino L.

Oncogene. 2013 Mar 14;32(11):1428-40. doi: 10.1038/onc.2012.154. Epub 2012 May 7.

16.

Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.

Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F.

Mol Cancer Ther. 2012 Jul;11(7):1528-38. doi: 10.1158/1535-7163.MCT-11-1020. Epub 2012 Mar 27.

17.

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683. Epub 2012 Mar 5.

18.

Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice.

Salvestrini V, Zini R, Rossi L, Gulinelli S, Manfredini R, Bianchi E, Piacibello W, Caione L, Migliardi G, Ricciardi MR, Tafuri A, Romano M, Salati S, Di Virgilio F, Ferrari S, Baccarani M, Ferrari D, Lemoli RM.

Blood. 2012 Jan 5;119(1):217-26. doi: 10.1182/blood-2011-07-370775. Epub 2011 Nov 3.

19.

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G, Aglietta M.

BMC Cancer. 2011 Jan 25;11:31. doi: 10.1186/1471-2407-11-31.

20.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
21.

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F.

BMC Cancer. 2010 Nov 18;10:631. doi: 10.1186/1471-2407-10-631.

22.

Inhibition of erythropoiesis in malaria anemia: role of hemozoin and hemozoin-generated 4-hydroxynonenal.

Skorokhod OA, Caione L, Marrocco T, Migliardi G, Barrera V, Arese P, Piacibello W, Schwarzer E.

Blood. 2010 Nov 18;116(20):4328-37. doi: 10.1182/blood-2010-03-272781. Epub 2010 Aug 4.

23.

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, Bottos A, Gammaitoni L, Migliardi G, Camussi G, Alberghini M, Torchio B, Ferrari S, Bussolino F, Fagioli F, Picci P, Aglietta M.

Mol Cancer. 2009 Dec 10;8:118. doi: 10.1186/1476-4598-8-118.

24.

Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene.

Leuci V, Gammaitoni L, Capellero S, Sangiolo D, Mesuraca M, Bond HM, Migliardi G, Cammarata C, Aglietta M, Morrone G, Piacibello W.

Stem Cells. 2009 Nov;27(11):2815-23. doi: 10.1002/stem.224.

25.

Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.

Migliardi G, Spina E, D'Arrigo C, Gagliano A, Germanò E, Siracusano R, Diaz FJ, de Leon J.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1496-501. doi: 10.1016/j.pnpbp.2009.08.009. Epub 2009 Aug 23.

PMID:
19706318
26.

Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.

Cavalloni G, Sarotto I, Pignochino Y, Gammaitoni L, Migliardi G, Sgro L, Piacibello W, Risio M, Aglietta M, Leone F.

Anticancer Drugs. 2008 Aug;19(7):689-96. doi: 10.1097/CAD.0b013e3283050083.

PMID:
18594210
27.

Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.

Migliardi G, D'Arrigo C, Santoro V, Bruno A, Cortese L, Campolo D, Cacciola M, Spina E.

Clin Neuropharmacol. 2007 Mar-Apr;30(2):107-13.

PMID:
17414943
28.

Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.

Spina E, D'Arrigo C, Migliardi G, Santoro V, Muscatello MR, Micò U, D'Amico G, Perucca E.

Ther Drug Monit. 2006 Oct;28(5):599-602.

PMID:
17038872
29.

Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.

D'Arrigo C, Migliardi G, Santoro V, Spina E.

Ther Drug Monit. 2006 Jun;28(3):388-93.

PMID:
16778724
30.

Serial transplantations in nonobese diabetic/severe combined immunodeficiency mice of transduced human CD34+ cord blood cells: efficient oncoretroviral gene transfer and ex vivo expansion under serum-free conditions.

Gammaitoni L, Lucchi S, Bruno S, Tesio M, Gunetti M, Pignochino Y, Migliardi G, Lazzari L, Aglietta M, Rebulla P, Piacibello W.

Stem Cells. 2006 May;24(5):1201-12. Epub 2006 Jan 12.

31.

Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia.

D'Arrigo C, Migliardi G, Santoro V, Morgante L, Muscatello MR, Ancione M, Spina E.

Pharmacol Res. 2005 Dec;52(6):497-501. Epub 2005 Oct 11.

PMID:
16226034
32.

Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.

Rosaria Muscatello M, Pacetti M, Cacciola M, La Torre D, Zoccali R, D'Arrigo C, Migliardi G, Spina E.

Epilepsia. 2005 May;46(5):771-4.

33.

Plasma risperidone concentrations during combined treatment with sertraline.

Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A.

Ther Drug Monit. 2004 Aug;26(4):386-90.

PMID:
15257068

Supplemental Content

Loading ...
Support Center